![]() No studies showed long-term beneficial hair growth. Only one study which compared two topical corticosteroids showed significant short-term benefits. We found 17 randomised controlled trials involving 540 participants. Also, there is no guarantee that any hair regrown during treatment will persist once the treatment is finished. Oral steroids may cause serious side effects. ![]() Some of the skin treatments can have unpleasant side effects such as itching or hair growth in areas of the body away from where the cream was applied. Treatments include a variety of different creams or lotions applied to the scalp such as topical or oral corticosteroids, minoxidil and some light-based therapies. Sometimes the condition will get better on its own, but in some cases it can get worse. It can affect the entire scalp (alopecia totalis) or cause loss of all body hair (alopecia universalis). The size and number of patches and progress of the disease can vary between people. Cases of AT and AU comprised approximately 9% of patients diagnosed with AA.Ĭonclusions and Relevance The findings of this cross-sectional study suggest that there is a significant burden of AA, AT, and AU in the US in which people of color, particularly Asian Americans, appear to be disproportionately affected.There is no good trial evidence that any treatments provide long-term benefit to patients with alopecia areata, alopecia totalis and alopecia universalis.Īlopecia areata is a condition that causes patchy hair loss. White patients had the lowest standardized prevalence (168 per 100 000 95% CI, 157-179) among racial and ethnic subgroups. The age-standardized prevalence ratio in women to men was 1.32. Overall age-and-sex standardized prevalences among adults and among children and adolescents were observed to be 0.18% and 0.10%, respectively. Results Of the 1 093 176 patients who met inclusion criteria, 1812 had at least 1 code for AA, 1216 female (67%) and 596 male (33%) patients. Main Outcomes and Measures Prevalent cases of AA, AT, and AU. The statistical analysis was conducted between July 21, 2022, and December 22, 2022. Objective To estimate overall and subgroup prevalences of AA and its subtypes.ĭesign, Setting, and Participants This cross-sectional study using electronic records comprising the Explorys database (Watson Health, IBM Corporation) included children, adolescents, and adults seeking healthcare across the 4 census regions in the US between January 1, 2019, and December 31, 2019. Importance Prevalences of alopecia areata (AA), alopecia totalis (AT), and alopecia universalis (AU) are poorly established.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |